These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2457 related articles for article (PubMed ID: 20628086)

  • 21. [The DREAM of diabetes prevention].
    Ruiz J
    Rev Med Suisse; 2007 Jan; 3(94):132, 134-6. PubMed ID: 17354538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Heart, diabetes and glitazones].
    Le Feuvre C
    Ann Endocrinol (Paris); 2004 Feb; 65(1 Suppl):S26-35. PubMed ID: 15163921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Experiences of the DREAM trial].
    Fövényi J
    Orv Hetil; 2006 Dec; 147(52):2523-6. PubMed ID: 17294577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
    Reyes-Morales H; Mino-León D; Doubova SV; Flores-Hernández S
    Int J Clin Pharmacol Ther; 2012 Jan; 50(1):1-9. PubMed ID: 22192639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.
    Berthet S; Olivier P; Montastruc JL; Lapeyre-Mestre M
    BMC Clin Pharmacol; 2011 May; 11():5. PubMed ID: 21609444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosiglitazone-induced anasarca without heart failure: capillary leakage?
    Dagdelen S; Kurt M; Aydin K; Bayraktar M
    Hormones (Athens); 2008; 7(2):180-3. PubMed ID: 18477557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dysglycemia and a history of reproductive risk factors.
    McDonald SD; Yusuf S; Sheridan P; Anand SS; Gerstein HC;
    Diabetes Care; 2008 Aug; 31(8):1635-8. PubMed ID: 18458144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.
    Hall GC; Smith HT; Curtis B; McMahon AD
    Int J Clin Pract; 2011 May; 65(5):586-91. PubMed ID: 21489082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Rosenstock J; Baron MA; Dejager S; Mills D; Schweizer A
    Diabetes Care; 2007 Feb; 30(2):217-23. PubMed ID: 17259484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.
    Loke YK; Kwok CS; Singh S
    BMJ; 2011 Mar; 342():d1309. PubMed ID: 21415101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
    Habib ZA; Tzogias L; Havstad SL; Wells K; Divine G; Lanfear DE; Tang J; Krajenta R; Pladevall M; Williams LK
    Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):437-47. PubMed ID: 19235778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage.
    Rennings AJ; Smits P; Stewart MW; Tack CJ
    Diabetologia; 2010 Sep; 53(9):1856-66. PubMed ID: 20499046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular risk of rosiglitazone: another perspective.
    Waksman JC
    J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rosiglitazone and heart failure: long-term vigilance.
    Singh N
    J Cardiovasc Pharmacol Ther; 2004 Mar; 9(1):21-5. PubMed ID: 15094965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms.
    Wang F; Vergara C; Carabino J; Desilets A; Vasquez R
    Am J Health Syst Pharm; 2004 Aug; 61(15):1604-8. PubMed ID: 15372837
    [No Abstract]   [Full Text] [Related]  

  • 36. The 11482G >A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes.
    Kang ES; Cha BS; Kim HJ; Kim HJ; Kim SH; Hur KY; Lee HJ; Shim WS; Ahn CW; Lee HC
    Diabetes Care; 2006 Jun; 29(6):1320-4. PubMed ID: 16732015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.
    Hsiao FY; Huang WF; Wen YW; Chen PF; Kuo KN; Tsai YW
    Drug Saf; 2009; 32(8):675-90. PubMed ID: 19591532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
    ; Gerstein HC; Yusuf S; Bosch J; Pogue J; Sheridan P; Dinccag N; Hanefeld M; Hoogwerf B; Laakso M; Mohan V; Shaw J; Zinman B; Holman RR
    Lancet; 2006 Sep; 368(9541):1096-105. PubMed ID: 16997664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety of rosiglitazone in the treatment of type 2 diabetes.
    Singh S; Loke YK
    Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cardiovascular effects of rosiglitazone].
    Le Feuvre C
    Presse Med; 2004 Jun; 33(11):735-45. PubMed ID: 15257231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 123.